These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 11805731)

  • 1. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
    Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
    Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
    Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
    Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
    Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
    Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
    Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
    J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
    Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
    Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
    Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of irinotecan disposition and toxicity: a review.
    Fujita K; Sparreboom A
    Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
    Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
    J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
    Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
    Rouits E; Charasson V; Pétain A; Boisdron-Celle M; Delord JP; Fonck M; Laurand A; Poirier AL; Morel A; Chatelut E; Robert J; Gamelin E
    Br J Cancer; 2008 Oct; 99(8):1239-45. PubMed ID: 18797458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
    Tanaka H; Saito K; Mino K; Izumi K; Harada M; Isobe H
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1505-9. PubMed ID: 19755821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
    Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
    Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer.
    Fukuda M; Okumura M; Iwakiri T; Arimori K; Honda T; Kobayashi K; Senju H; Takemoto S; Ikeda T; Yamaguchi H; Nakatomi K; Matsuo N; Mukae H; Ashizawa K
    Thorac Cancer; 2018 Jan; 9(1):51-58. PubMed ID: 29052349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
    Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV
    J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
    Gupta E; Wang X; Ramirez J; Ratain MJ
    Cancer Chemother Pharmacol; 1997; 39(5):440-4. PubMed ID: 9054958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.
    Ishikawa K; Kajita Y; Hasegawa Y; Noda Y; Yoshida J; Nabeshima T
    J Neurooncol; 2005 Sep; 74(3):283-6. PubMed ID: 16187025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.